




E. Meggers

The author presented on this page has recently published his **10th article** in *Angewandte Chemie* in the last 10 years:

“An Organometallic Inhibitor for the Human Repair Enzyme 7,8-Dihydro-8-oxo-guanosine Triphosphatase”: M. Streib, K. Kräling, K. Richter, X. Xie, H. Steuber, E. Meggers, *Angew. Chem.* **2014**, 126, 311–315; *Angew. Chem. Int. Ed.* **2014**, 53, 305–309.



The work of E. Meggers has been featured on the cover of *Angewandte Chemie*: “Isomerization-Induced Asymmetric Coordination Chemistry: From Auxiliary Control to Asymmetric Catalysis”: L. Gong, Z. Lin, K. Harms, E. Meggers, *Angew. Chem.* **2010**, 122, 8127–8129; *Angew. Chem. Int. Ed.* **2010**, 49, 7955–7957.

## Eric Meggers

<b>Date of birth:</b>	May 10, 1968
<b>Position:</b>	Professor, Department of Chemistry, University of Marburg, and College of Chemistry and Chemical Engineering, Xiamen University
<b>E-mail:</b>	meggers@chemie.uni-marburg.de
<b>Homepage:</b>	http://www.uni-marburg.de/fb15/ag-meggers
<b>Education:</b>	1990–1995 Diploma, University of Bonn 1995–1999 PhD supervised by B. Giese, University of Basel 1999–2002 Postdoc with P. G. Schultz, The Scripps Research Institute, La Jolla
<b>Awards:</b>	2002 Camille and Henry Dreyfus New Faculty Award; 2006 Camille Dreyfus Teacher-Scholar Award; Nanqiang Lectureship Award, Xiamen University; 2006–2008 Alfred P. Sloan Research Fellow; 2009–2010 Novartis Chemistry Lectureship Award
<b>Current research interests:</b>	Metal-containing enzyme inhibitors; chiral-at-metal complexes for asymmetric catalysis; asymmetric coordination chemistry; organometallic catalysis in biological systems
<b>Hobbies:</b>	Playing chess and, upon retirement, hopefully returning to doing experimental research

**My favorite food is ...** anything with curry.

**My favorite place on earth is ...** San Diego, closely followed by Xiamen.

**I like refereeing because ...** it forces me to engage myself with a single piece of work in detail.

**The most significant scientific advance of the last 100 years has been ...** the amazing advances in analytical methods.

**The biggest problem that scientists face is ...** that they don't have enough time to do science.

**What I look for first in a publication is ...** a clear message.

**My favorite piece of research is ...** Alfred Werner's contributions to octahedral stereochemistry.

**If I won the lottery, I would ...** definitely not use it for funding my own research.

**I chose chemistry as a career because ...** of fortunate circumstances, since I actually started studying physics and mathematics.

**My secret/not-so-secret passion is ...** eating candy.

**If I were not a scientist, I would be ...** an architect. I just enjoy thinking about the design of attractive yet functional working and living environments.

### My 5 top papers:

1. “Asymmetric Catalysis with Substitutionally Labile yet Stereochemically Stable Chiral-at-Metal Iridium(III) Complex”: H. Huo, C. Fu, K. Harms, E. Meggers, *J. Am. Chem. Soc.* **2014**, 136, 2990–2993. (The chiral Lewis acid catalyst exploits metal centrochirality as the sole element of chirality.)
2. “Asymmetric Catalysis with Inert Chiral-at-Metal Iridium Complex”: L.-A. Chen, W. Xu, B. Huang, J. Ma, L. Wang, J. Xi, K. Harms, L. Gong, E. Meggers, *J. Am. Chem. Soc.* **2013**, 135, 10598–10601. (Organocatalysis with the organic ligand sphere of a metal complex.)
3. “Chiral-Auxiliary-Mediated Asymmetric Synthesis of Ruthenium Polypyridyl Complexes”: L. Gong, M. Wenzel, E. Meggers, *Acc. Chem. Res.* **2013**, 46, 2635–2644. (Summarizes our developed strategies for the asymmetric synthesis of chiral metal complexes.)
4. “Structurally Sophisticated Octahedral Metal Complexes as Highly Selective Protein Kinase Inhibitors”: L. Feng et al., *J. Am. Chem. Soc.* **2011**, 133, 5976–5986. (Demonstrates the merit of using inert octahedral metal complexes as scaffolds for the design of enzyme inhibitors.)
5. “Exploring Chemical Space with Organometallics: Ruthenium Complexes as Protein Kinase Inhibitors”: E. Meggers, G. E. Atilla-Gokcumen, H. Bregman, J. Maksimoska, S. P. Mulcahy, N. Pagano, D. S. Williams, *Synlett* **2007**, 8, 1177–1189. (Summarizes our early work on exploiting kinetically inert organometallics as protein kinase inhibitors.)

DOI: 10.1002/anie.201403996